NYSEAMERICAN:PFNX - Pfenex Stock Price, Price Target & More

$5.42 -0.14 (-2.52 %)
(As of 04/20/2018 01:13 AM ET)
Previous Close$5.56
Today's Range$5.38 - $5.66
52-Week Range$2.07 - $6.77
Volume42,728 shs
Average Volume122,876 shs
Market Capitalization$106.11 million
P/E RatioN/A
Dividend YieldN/A
Beta3.6

About Pfenex (NYSEAMERICAN:PFNX)

Pfenex logoPfenex Inc., a clinical-stage biotechnology company, develops biosimilar therapeutics in the United States. The company's lead product candidates include PF708, a therapeutic equivalent candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that are in Phase I study. It develops PF529, a biosimilar candidate to Neulasta; PF530, a biosimilar candidate to Betaseron; and hematology/oncology products, including PF743 and PF745. The company has collaboration agreement with Jazz Pharmaceuticals Ireland Limited and Hospira, Inc., as well as a contract agreement with The National Institute of Allergy and Infectious Diseases. Pfenex Inc. is headquartered in San Diego, California.

Receive PFNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PFNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:PFNX
CUSIPN/A
Phone+1-858-3524400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-175.52%
Return on Equity-63.57%
Return on Assets-46.31%

Miscellaneous

EmployeesN/A
Outstanding Shares23,580,000

How to Become a New Pot Stock Millionaire

Pfenex (NYSEAMERICAN:PFNX) Frequently Asked Questions

What is Pfenex's stock symbol?

Pfenex trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "PFNX."

How were Pfenex's earnings last quarter?

Pfenex (NYSEAMERICAN:PFNX) released its quarterly earnings data on Thursday, March, 15th. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts' consensus estimates of $0.22 by $0.01. The biotechnology company earned $17.91 million during the quarter, compared to analyst estimates of $5 million. Pfenex had a negative net margin of 175.52% and a negative return on equity of 63.57%. View Pfenex's Earnings History.

When is Pfenex's next earnings date?

Pfenex is scheduled to release their next quarterly earnings announcement on Monday, May, 14th 2018. View Earnings Estimates for Pfenex.

What price target have analysts set for PFNX?

3 brokers have issued twelve-month target prices for Pfenex's shares. Their predictions range from $8.00 to $8.00. On average, they anticipate Pfenex's share price to reach $8.00 in the next year. View Analyst Ratings for Pfenex.

Are investors shorting Pfenex?

Pfenex saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 206,985 shares, an increase of 38.4% from the March 15th total of 149,543 shares. Based on an average daily volume of 176,381 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.0% of the company's stock are short sold.

Who are some of Pfenex's key competitors?

Who are Pfenex's key executives?

Pfenex's management team includes the folowing people:
  • Dr. Hubert C. Chen, Chief Medical & Scientific Officer (Age 49)
  • Mr. Evert B. Schimmelpennink, CEO, Pres, Sec. & Director (Age 46)
  • Ms. Susan A. Knudson, Chief Financial Officer (Age 54)
  • Ms. Patricia Lady C.M.A., C.P.A., M.B.A., CPA, MBA CMA, Chief Accounting Officer (Age 60)
  • Mr. Patrick K. Lucy, Chief Bus. Officer (Age 50)

Has Pfenex been receiving favorable news coverage?

Media headlines about PFNX stock have trended somewhat positive on Friday, Accern reports. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pfenex earned a news sentiment score of 0.10 on Accern's scale. They also assigned news headlines about the biotechnology company an impact score of 45.62 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Pfenex?

Shares of PFNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pfenex's stock price today?

One share of PFNX stock can currently be purchased for approximately $5.42.

How big of a company is Pfenex?

Pfenex has a market capitalization of $106.11 million.

How can I contact Pfenex?

Pfenex's mailing address is 10790 Roselle St, SAN DIEGO, CA 92121-1508, United States. The biotechnology company can be reached via phone at +1-858-3524400.


MarketBeat Community Rating for Pfenex (PFNX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  134 (Vote Outperform)
Underperform Votes:  102 (Vote Underperform)
Total Votes:  236
MarketBeat's community ratings are surveys of what our community members think about Pfenex and other stocks. Vote "Outperform" if you believe PFNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pfenex (NYSEAMERICAN:PFNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Pfenex in the last 12 months. Their average twelve-month price target is $8.00, suggesting that the stock has a possible upside of 47.60%. The high price target for PFNX is $8.00 and the low price target for PFNX is $8.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $8.00$8.00$8.00N/A
Price Target Upside: 47.60% upside56.86% upside151.57% upsideN/A

Pfenex (NYSEAMERICAN:PFNX) Consensus Price Target History

Price Target History for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN:PFNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
3/29/2018BarclaysSet Price TargetOverweight -> Buy$14.00 -> $8.00View Rating Details
3/16/2018William BlairReiterated RatingOutperformView Rating Details
11/10/2017JMP SecuritiesLower Price TargetPositive -> Outperform$21.00 -> $8.00View Rating Details
8/9/2016MizuhoLower Price TargetBuy$22.00 -> $18.00View Rating Details
(Data available from 4/20/2016 forward)

Earnings

Pfenex (NYSEAMERICAN:PFNX) Earnings History and Estimates Chart

Earnings by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN:PFNX) Earnings Estimates

2019 EPS Consensus Estimate: ($1.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20191($0.33)($0.33)($0.33)
Q2 20191($0.35)($0.35)($0.35)
Q3 20191($0.44)($0.44)($0.44)
Q4 20191($0.41)($0.41)($0.41)

Pfenex (NYSEAMERICAN PFNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.58)N/AView Earnings Details
3/15/2018Q4 2017$0.22$0.23$5.00 million$17.91 millionViewN/AView Earnings Details
11/9/2017Q3 2017($0.54)($0.37)$3.30 million$5.02 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.46)($0.52)$3.10 million$3.03 millionViewListenView Earnings Details
5/8/2017Q1 2017($0.57)($0.43)$2.50 million$2.80 millionViewListenView Earnings Details
3/15/2017Q4 2016($0.66)($0.45)$2.50 million$5.47 millionViewN/AView Earnings Details
11/9/2016Q316($0.56)$1.46$3.18 million$48.82 millionViewListenView Earnings Details
8/8/2016Q216($0.47)($0.43)$2.55 million$3.10 millionViewN/AView Earnings Details
5/9/2016Q116($0.45)($0.35)$2.35 million$2.76 millionViewN/AView Earnings Details
3/10/2016Q415($0.59)($0.37)$2.56 million$3.30 millionViewListenView Earnings Details
11/13/2015Q315($0.46)($0.33)$2.05 million$2.06 millionViewListenView Earnings Details
8/13/2015Q215($0.39)($0.27)$2.07 million$2.30 millionViewListenView Earnings Details
5/14/2015Q115($0.24)($0.29)$2.10 million$2.00 millionViewListenView Earnings Details
3/16/2015Q4($0.20)($0.18)$2.05 million$2.02 millionViewN/AView Earnings Details
11/13/2014Q3($0.25)($0.16)$2.13 million$2.80 millionViewN/AView Earnings Details
8/29/2014($0.15)($1.67)$1.75 million$3.27 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pfenex (NYSEAMERICAN:PFNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pfenex (NYSEAMERICAN PFNX) Insider Trading and Institutional Ownership History

Insider Trading History for Pfenex (NYSEAMERICAN:PFNX)
Institutional Ownership by Quarter for Pfenex (NYSEAMERICAN:PFNX)

Pfenex (NYSEAMERICAN PFNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/12/2017Jason Grenfell-GardnerDirectorBuy10,000$4.51$45,100.0010,000View SEC Filing  
5/16/2017Patricia LadyInsiderSell2,000$4.78$9,560.00View SEC Filing  
1/6/2017Signet Healthcare Partners AccMajor ShareholderSell400$9.50$3,800.00View SEC Filing  
1/5/2017Signet Healthcare Partners AccMajor ShareholderSell7,710$9.50$73,245.00View SEC Filing  
12/29/2016Signet Healthcare Partners AccMajor ShareholderSell24,104$9.66$232,844.64View SEC Filing  
12/27/2016Signet Healthcare Partners AccMajor ShareholderSell104,600$9.58$1,002,068.00View SEC Filing  
12/22/2016Signet Healthcare Partners AccMajor ShareholderSell10,896$9.61$104,710.56View SEC Filing  
11/21/2016Patricia LadyInsiderSell2,000$9.87$19,740.004,800View SEC Filing  
11/15/2016Patrick K. LucyInsiderSell5,000$10.04$50,200.00View SEC Filing  
8/18/2016Patricia LadyInsiderSell2,000$9.42$18,840.00View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.004,100View SEC Filing  
5/24/2016Patricia LadyCAOSell2,000$6.52$13,040.004,100View SEC Filing  
12/15/2015Chemical Co /De/ DowMajor ShareholderSell600,000$11.75$7,050,000.002,221,428View SEC Filing  
12/3/2015Patrick K LucyInsiderSell1,500$14.15$21,225.00105,690View SEC Filing  
12/1/2015Bertrand C. LiangCEOSell5,000$14.88$74,400.00522,466View SEC Filing  
12/1/2015Henry W Jr. TalbotVPSell2,000$15.08$30,160.00118,678View SEC Filing  
11/18/2015Patricia LadyCAOSell2,000$14.05$28,100.001,400View SEC Filing  
11/4/2015Patrick K. LucyinsiderSell1,500$17.54$26,310.00107,190View SEC Filing  
11/2/2015Bertrand C LiangCEOSell5,000$18.01$90,050.00527,466View SEC Filing  
10/2/2015Patrick K LucyInsiderSell1,500$14.98$22,470.00108,690View SEC Filing  
10/1/2015Bertrand C LiangCEOSell5,000$14.78$73,900.00532,466View SEC Filing  
9/3/2015Patricia LadyCAOSell2,000$20.48$40,960.001,400View SEC Filing  
9/3/2015Patrick K LucyInsiderSell1,500$20.91$31,365.00110,190View SEC Filing  
9/1/2015Bertrand C. LiangCEOSell5,000$21.02$105,100.00536,980View SEC Filing  
7/6/2015Patrick K LucyInsiderSell1,500$19.17$28,755.00View SEC Filing  
7/1/2015Bertrand C LiangCEOSell5,000$19.63$98,150.00View SEC Filing  
6/3/2015Patrick K LucyInsiderSell1,500$20.08$30,120.00View SEC Filing  
6/1/2015Bertrand C LiangCEOSell5,000$18.70$93,500.00View SEC Filing  
5/4/2015Patrick K LucyInsiderSell1,500$13.25$19,875.00View SEC Filing  
5/1/2015Bertrand C LiangCEOSell5,000$13.49$67,450.00View SEC Filing  
4/29/2015Chemical Co /De/ DowMajor ShareholderSell2,232,233$14.57$32,523,634.81View SEC Filing  
4/29/2015James C GaleDirectorSell1,907,767$14.57$27,796,165.19View SEC Filing  
4/2/2015Patrick K LucyInsiderSell1,500$17.62$26,430.00View SEC Filing  
4/1/2015Bertrand C LiangCEOSell5,000$15.27$76,350.00View SEC Filing  
3/4/2015Patrick K LucyInsiderSell1,500$14.36$21,540.00View SEC Filing  
7/29/2014Signet Healthcare Partners AccMajor ShareholderSell380,867$0.31$118,068.77View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pfenex (NYSEAMERICAN PFNX) News Headlines

Source:
DateHeadline
Pfenex (PFNX) Reports Development & License Agreement with NT Pharma Group for PF708 Therapeutic Equivalent Candidate to ForteoPfenex (PFNX) Reports Development & License Agreement with NT Pharma Group for PF708 Therapeutic Equivalent Candidate to Forteo
www.streetinsider.com - April 19 at 9:28 AM
Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenexs PF708 Therapeutic Equivalent Candidate to Forteo®Pfenex and NT Pharma Enter into a Development and License Agreement for Pfenex's PF708 Therapeutic Equivalent Candidate to Forteo®
finance.yahoo.com - April 19 at 9:28 AM
BRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenexs PF708 Therapeutic Equivalent Candidate To ForteoBRIEF-Pfenex And NT Pharma Enter Into A Development And License Agreement For Pfenex's PF708 Therapeutic Equivalent Candidate To Forteo
finance.yahoo.com - April 19 at 9:28 AM
Pfenex (PFNX) Upgraded at Zacks Investment ResearchPfenex (PFNX) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 18 at 5:18 PM
Pfenex (PFNX) Upgraded to "Buy" by Zacks Investment ResearchPfenex (PFNX) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:40 AM
Pfenex Inc (PFNX) Short Interest Up 38.4% in MarchPfenex Inc (PFNX) Short Interest Up 38.4% in March
www.americanbankingnews.com - April 10 at 6:34 PM
Pfenex (PFNX) Stock Rating Lowered by Zacks Investment ResearchPfenex (PFNX) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 10 at 12:01 PM
Pfenex (PFNX) Lowered to Hold at Zacks Investment ResearchPfenex (PFNX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 7:02 AM
Pfenex (PFNX) Raised to "Buy" at Zacks Investment ResearchPfenex (PFNX) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:18 PM
Pfenex (PFNX) Given a $8.00 Price Target by Barclays AnalystsPfenex (PFNX) Given a $8.00 Price Target by Barclays Analysts
www.americanbankingnews.com - March 30 at 6:14 PM
Pfenex (PFNX) Raised to Buy at Zacks Investment ResearchPfenex (PFNX) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:22 PM
Pfenex (PFNX) Lifted to Buy at Zacks Investment ResearchPfenex (PFNX) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - March 23 at 9:34 PM
Pfenex (PFNX) Downgraded to Hold at Zacks Investment ResearchPfenex (PFNX) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - March 23 at 7:54 AM
Equities Analysts Set Expectations for Pfenex Incs Q1 2019 Earnings (PFNX)Equities Analysts Set Expectations for Pfenex Inc's Q1 2019 Earnings (PFNX)
www.americanbankingnews.com - March 19 at 5:02 AM
BRIEF-Pfenex Says Entered Sales Agreement To Sell Shares Having Aggregate Sales Proceeds Of Up To $20 MlnBRIEF-Pfenex Says Entered Sales Agreement To Sell Shares Having Aggregate Sales Proceeds Of Up To $20 Mln
www.reuters.com - March 17 at 5:04 PM
Pfenexs (PFNX) CEO Evert Schimmelpennink on Q4 2017 Results - Earnings Call TranscriptPfenex's (PFNX) CEO Evert Schimmelpennink on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 17 at 5:04 PM
Pfenex (PFNX) Rating Reiterated by William BlairPfenex (PFNX) Rating Reiterated by William Blair
www.americanbankingnews.com - March 16 at 6:06 PM
Edited Transcript of PFNX earnings conference call or presentation 15-Mar-18 8:30pm GMTEdited Transcript of PFNX earnings conference call or presentation 15-Mar-18 8:30pm GMT
finance.yahoo.com - March 16 at 5:25 PM
Pfenex posts 4Q profitPfenex posts 4Q profit
www.cnbc.com - March 15 at 4:56 PM
Pfenex, Inc. to Host Earnings CallPfenex, Inc. to Host Earnings Call
finance.yahoo.com - March 15 at 4:56 PM
Pfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business UpdatePfenex Reports Fourth Quarter and Full Year 2017 Results and Provides Business Update
finance.yahoo.com - March 15 at 4:56 PM
One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)One Thing To Consider Before Buying Pfenex Inc (NYSEMKT:PFNX)
finance.yahoo.com - March 15 at 9:23 AM
Pfenex Inc. to Present at Oppenheimers 28th Annual Healthcare ConferencePfenex Inc. to Present at Oppenheimer's 28th Annual Healthcare Conference
finance.yahoo.com - March 13 at 6:20 PM
Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018Pfenex to Report Fourth Quarter and Full Year 2017 Results and Provide Business Update on Thursday, March 15, 2018
finance.yahoo.com - March 8 at 5:20 PM
Pfenex (PFNX) Set to Announce Quarterly Earnings on TuesdayPfenex (PFNX) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - March 6 at 2:32 AM
BRIEF-Deerfield Mgmt Reports 5.32 Pct Passive Stake In Pfenex Inc As Of Feb 23BRIEF-Deerfield Mgmt Reports 5.32 Pct Passive Stake In Pfenex Inc As Of Feb 23
www.reuters.com - March 3 at 9:25 AM
Pfenex Inc. to Present at Barclays 2018 Global Healthcare ConferencePfenex Inc. to Present at Barclay's 2018 Global Healthcare Conference
finance.yahoo.com - February 27 at 5:02 PM
Pfenex Inc (PFNX) Short Interest UpdatePfenex Inc (PFNX) Short Interest Update
www.americanbankingnews.com - February 9 at 6:36 PM
Pfenex Inc (PFNX) Short Interest Up 33.2% in JanuaryPfenex Inc (PFNX) Short Interest Up 33.2% in January
www.americanbankingnews.com - January 24 at 5:40 PM
Short Interest in Pfenex Inc (PFNX) Increases By 13.4%Short Interest in Pfenex Inc (PFNX) Increases By 13.4%
www.americanbankingnews.com - January 10 at 6:06 PM
Pfenex (PFNX) Downgraded to "Sell" at Zacks Investment ResearchPfenex (PFNX) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 7 at 11:53 AM
Pfenex Names Susan A. Knudson as Chief Financial OfficerPfenex Names Susan A. Knudson as Chief Financial Officer
finance.yahoo.com - January 4 at 10:05 AM
Pfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018Pfênex, Inc. :PFNX-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 10:01 AM
Pfenex Inc to Post FY2017 Earnings of ($1.11) Per Share, William Blair Forecasts (PFNX)Pfenex Inc to Post FY2017 Earnings of ($1.11) Per Share, William Blair Forecasts (PFNX)
www.americanbankingnews.com - December 21 at 8:40 AM
Pfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz PharmaceuticalsPfenex earns $18.5 million in milestones and updates Worldwide License and Option Agreement with Jazz Pharmaceuticals
finance.yahoo.com - December 19 at 10:12 AM
Zacks Investment Research Downgrades Pfenex Inc. (PFNX) to HoldZacks Investment Research Downgrades Pfenex Inc. (PFNX) to Hold
www.americanbankingnews.com - November 19 at 11:36 PM

SEC Filings

Pfenex (NYSEAMERICAN:PFNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Pfenex (NYSEAMERICAN PFNX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.